Skip to Main Content

After months of suspense, two pharmaceutical industry trade groups have agreed to drop a lawsuit against the state of Nevada over a new law that requires drug makers to report a wide array of pricing information about their diabetes medicines.

The move comes just weeks after state officials modified a regulation to allow companies to mark certain pricing data as confidential when they begin complying with the new transparency law, according to court documents.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED